Analyst Conference Summary

Vascular Biogenics
(VBL Therapeutics)

VBLT

conference date: March 15, 2018 @ 5:30 AM Pacific Time
for quarter ending: December 31, 2018 (Q4, fourth quarter 2017)


Forward-looking statements

Overview: Lead gene therapy drug failed Phase 3 in one indication, but has a shot with ovarian cancer Phase 3 now underway.

Basic data (GAAP):

For the full year 2017:

Revenue was $13.8 million.

Net loss was $10.2 million.

Loss per share was $0.37.

Guidance:

none

Conference Highlights:

Dror Harats, M.D., CEO of VBL Therapeutics, said "VBL has more than $50 million in cash, which will enable us to continue the development of VB-111 and our promising pipeline through 2020. We intend to continue the ongoing OVAL trial, our Phase 3 potential registration trial in platinum-resistant ovarian cancer, in collaboration with the GOG Foundation. We intend to add an interim analysis for evidence of efficacy signal in our OVAL trial, sooner than in our original plan. We expect that the interim readout may be available during the first half of 2019."

But the Phase 3 trial of VB-111 plus Avastin for recurrent glioblastoma failed (to be significantly better than Avastin alone). Investigating why positive Phase 2 data was not replicated in Phase 3.

The Phase 3 trial of VB-111 with chemotherapy in platinum-resistant ovarian cancer started. 350 patients will be enrolled. VB-111 has orphan drug designation in this indication. There will be an interim analysis in the first half of 2019.

A license agreement was signed with NanoCarrier for VB-111 in Japan. A milestone payment was received in February.

Has a strong preclinical pipeline.

A new gene therapy manufacturing plant was opened in Modiin, Israel.

Cash ended the quarter at $54.7 million. In November raised $18.75 million with a common stock offering.

Full year 2017: Cost of revenue was $0.34 million. Gross profit $13.5 million. R&D expense $17.8 million. SG&A $6.4 million. Operating loss $10.7 million. Other income $0.5 million.

Q&A:

GBM study responders, when might we see that data? We are still waiting for more data to come. It is hard to know when we will have more information for the market, but perhaps in Q2. There are some patients still taking the combination who remain in full remission, and we will enable them to stay on the drug. "The difference between the Phase 2 and Phase 3 is a big difference."

We do know that in the successful Phase 2 study we gave 111 first to prime patients, then gave Avastin. For the failed Phase 3 trial the FDA insisted we give Avastin first, then 111.

Ovarian analysis interim analysis plan? Still discussing with the trial steering committee and FDA. Looking at biomarkers to see if we are repeating Phase 2 positive results. We had already planned a futility analysis, we are just moving up the timeline, if the FDA agrees. We should be able to give firm information in Q2. The trial will be double blind, and we have not recruited many patients so far, since we know we are changing it.

Preclinical to clinical plan? We are still optimizing antibodies, need to do toxicology.

VBL-201? Will be more willing to discuss it in the near future.

OpenIcon Analyst Conference Summaries Main Page

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 
 

Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers